Aprea Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 7
- Market Cap
- $19.1M
- Website
- http://www.aprea.com
- Introduction
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva,...
Study of APR-1051 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 79
- Registration Number
- NCT06260514
- Locations
- 🇺🇸
NEXT Oncology -San Antonio, San Antonio, Texas, United States
🇺🇸MD Anderson Cancer Center (MDACC), Houston, Texas, United States
🇺🇸NEXT Oncology -Dallas, Irving, Texas, United States
Study Of ATRN-119 In Patients With Advanced Solid Tumors
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT04905914
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University Hospitals, Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT04638309
- Locations
- 🇺🇸
Dana Farber Cancer Institue, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04419389
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT04383938
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 51
- Registration Number
- NCT04214860
- Locations
- 🇺🇸
Northwestern Medicine, Chicago, Illinois, United States
🇺🇸H. Lee Moffitt CC, Tampa, Florida, United States
🇺🇸Weill Cornell Cancer Center, New York, New York, United States
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03931291
- Locations
- 🇺🇸
Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 154
- Registration Number
- NCT03745716
- Locations
- 🇺🇸
Washington University St. Louis, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇫🇷CHU Nantes, Nantes, France
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03391050
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇧🇪CHU UCL Namur - site Sainte-Elisabeth, Namur, Belgium
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03268382
- Locations
- 🇪🇸
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
🇧🇪Centre Hospitalier Universitaire de Liège, Liège, Belgium
🇬🇧Imperial College London, Hammersmith Hospital Campus, London, United Kingdom